DK3347054T3 - Dosisregimer til anti-TF-antistoflægemiddelkonjugater - Google Patents
Dosisregimer til anti-TF-antistoflægemiddelkonjugater Download PDFInfo
- Publication number
- DK3347054T3 DK3347054T3 DK16765958.0T DK16765958T DK3347054T3 DK 3347054 T3 DK3347054 T3 DK 3347054T3 DK 16765958 T DK16765958 T DK 16765958T DK 3347054 T3 DK3347054 T3 DK 3347054T3
- Authority
- DK
- Denmark
- Prior art keywords
- drug conjugates
- antibody drug
- dosage regimens
- regimens
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217320P | 2015-09-11 | 2015-09-11 | |
| PCT/EP2016/071336 WO2017042352A1 (en) | 2015-09-11 | 2016-09-09 | Dosing regimens for anti-tf-antibody drug-conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3347054T3 true DK3347054T3 (da) | 2021-07-19 |
Family
ID=56926176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16765958.0T DK3347054T3 (da) | 2015-09-11 | 2016-09-09 | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190030178A1 (enExample) |
| EP (2) | EP3919081A1 (enExample) |
| JP (2) | JP6978409B2 (enExample) |
| CY (1) | CY1124532T1 (enExample) |
| DK (1) | DK3347054T3 (enExample) |
| ES (1) | ES2877527T3 (enExample) |
| HU (1) | HUE055109T2 (enExample) |
| PL (1) | PL3347054T3 (enExample) |
| PT (1) | PT3347054T (enExample) |
| SI (1) | SI3347054T1 (enExample) |
| WO (1) | WO2017042352A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20241036T1 (hr) | 2013-11-21 | 2024-11-08 | Genmab A/S | Liofilizirana formulacija konjugata protutijelo-lijek |
| US20210177987A1 (en) * | 2017-11-02 | 2021-06-17 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| JP7653013B2 (ja) | 2018-01-04 | 2025-03-28 | アイコニック セラピューティクス リミテッド ライアビリティ カンパニー | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| UA129351C2 (uk) * | 2018-03-07 | 2025-03-26 | Генмаб А/С | Кон'югат антитіла до тканинного фактора з лікарським засобом та його застосування для лікування раку |
| TWI841554B (zh) * | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CA3099547A1 (en) * | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| EP3836950A4 (en) * | 2018-08-16 | 2022-04-06 | Genmab A/S | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| JP7406784B2 (ja) * | 2019-04-17 | 2023-12-28 | 国立大学法人金沢大学 | 卵巣癌の検出方法 |
| TW202131954A (zh) * | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法 |
| JP2023500888A (ja) * | 2019-11-07 | 2023-01-11 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP2727606A3 (en) * | 2008-09-08 | 2015-09-23 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| EP2376110B1 (en) | 2009-01-09 | 2019-03-13 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| SMT201700547T1 (it) | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| HRP20241036T1 (hr) | 2013-11-21 | 2024-11-08 | Genmab A/S | Liofilizirana formulacija konjugata protutijelo-lijek |
-
2016
- 2016-09-09 US US15/758,520 patent/US20190030178A1/en not_active Abandoned
- 2016-09-09 JP JP2018512876A patent/JP6978409B2/ja active Active
- 2016-09-09 EP EP21171350.8A patent/EP3919081A1/en not_active Withdrawn
- 2016-09-09 WO PCT/EP2016/071336 patent/WO2017042352A1/en not_active Ceased
- 2016-09-09 PT PT167659580T patent/PT3347054T/pt unknown
- 2016-09-09 PL PL16765958T patent/PL3347054T3/pl unknown
- 2016-09-09 HU HUE16765958A patent/HUE055109T2/hu unknown
- 2016-09-09 DK DK16765958.0T patent/DK3347054T3/da active
- 2016-09-09 SI SI201631250T patent/SI3347054T1/sl unknown
- 2016-09-09 EP EP16765958.0A patent/EP3347054B1/en active Active
- 2016-09-09 ES ES16765958T patent/ES2877527T3/es active Active
-
2021
- 2021-07-26 CY CY20211100669T patent/CY1124532T1/el unknown
- 2021-08-12 JP JP2021131502A patent/JP2021181479A/ja active Pending
- 2021-12-10 US US17/548,436 patent/US20220265844A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6978409B2 (ja) | 2021-12-08 |
| SI3347054T1 (sl) | 2021-08-31 |
| JP2021181479A (ja) | 2021-11-25 |
| US20190030178A1 (en) | 2019-01-31 |
| EP3347054A1 (en) | 2018-07-18 |
| ES2877527T3 (es) | 2021-11-17 |
| HUE055109T2 (hu) | 2021-11-29 |
| PL3347054T3 (pl) | 2021-11-29 |
| EP3919081A1 (en) | 2021-12-08 |
| US20220265844A1 (en) | 2022-08-25 |
| WO2017042352A1 (en) | 2017-03-16 |
| PT3347054T (pt) | 2021-07-15 |
| EP3347054B1 (en) | 2021-05-05 |
| CY1124532T1 (el) | 2022-07-22 |
| JP2018532715A (ja) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291073A (en) | Drug conjugates of anti-egfr antibodies | |
| IL259651A (en) | Conjugations between an antibody to a specific her2 site and a drug | |
| IL272304A (en) | Bcma monoclonal antibody-drug conjugate | |
| IL267003A (en) | Multidrug antibody conjugates | |
| EP3473270A4 (en) | ANTIBODY-drug conjugate | |
| DK3386541T3 (da) | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab | |
| IL252015A0 (en) | Antibody drug conjugates | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| DK3236943T3 (da) | Sammensætninger til ileo-jejunal lægemiddeladministration | |
| DK3337539T3 (da) | Medikamenttilførselsanordning til variable enkeltdoser | |
| SG10202002153PA (en) | Glycoengineered antibody drug conjugates | |
| IL250189A0 (en) | Anti–cdh6 antibody drug conjugates | |
| SI3529248T1 (sl) | Farmacevtske spojine | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| DK3672631T5 (da) | Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| HUE054500T2 (hu) | MET antitest hatóanyag konjugátumok | |
| DK3383385T3 (da) | Melflufen-doseringsregimer for cancer | |
| LT3256154T (lt) | Farmacinė kompozicija, apimanti antikūną | |
| DK3199175T3 (da) | Farmaceutisk sammensætning til injektion | |
| LU92659B1 (en) | Glycooptimized antibody drug conjugates | |
| EP3330376A4 (en) | ANTI-EVA 1 PROTEIN ANTIBODY | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| DK3247394T3 (da) | Farmaceutisk formulering omfattende anti-egfr-antistof | |
| DK3247429T3 (da) | Indretning til en lægemiddeladministrationsanordning |